- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Anika Therapeutics Inc
+ Add to WatchlistANIK:US
17.5400 USD 0.0100 0.06%As of 20:10:00 ET on 06/19/2013.
Snapshot for Anika Therapeutics Inc (ANIK)
| Open: | 17.7200 | Day's Range: | 17.0000 - 18.0700 | Volume: | 168,034 |
|---|---|---|---|---|---|
| Previous Close: | 17.5500 | 52wk Range: | 9.1300 - 18.0700 | 1-Yr Rtn: | +27.38% |
Key Statistics for ANIK
| Current P/E Ratio (ttm) | 17.8980 |
|---|---|
| Estimated P/E(12/2013) | 17.8980 |
| Relative P/E vs. SPX | 1.1216 |
| Earnings Per Share (USD) (ttm) | 0.9800 |
| Est. EPS (USD) (12/2013) | 0.9800 |
| Est. PEG Ratio | 0.8949 |
| Market Cap (M USD) | 245.49 |
| Shares Outstanding (M) | 14.00 |
| 30 Day Average Volume | 72,226 |
| Price/Book (mrq) | 2.1774 |
| Price/Sale (ttm) | 3.2332 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ANIK
Company Profile & Key Executives for ANIK
Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products and devices. The Company's products, based on hyaluronic acid, promote the repair, protection, and healing of bone, cartilage, and soft tissue. Anika's products include ORTHOVISC and HYVISC which treat osteoarthritis.
| Charles H SherwoodPresident/CEO | Sylvia CheungCFO/Treasurer/Secretary |
| Frank J LuppinoChief Operating Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ANIK News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page